Sudo Biosciences Announces Second Close of Upsized Series B Financing Bringing Total Raised in Round to $147M
PRIVATEFeb 13, 2024
Amount Raised
$147 Million
Round Type
Series B
CarmelBiotechnologyHealth CareTherapeuticsBiopharmaBiotechnology Research
Investors
Dementia Discovery FundVelosity CapitalEventide Asset ManagementMonograph CapitalSurveyor CapitalFrazier Life SciencesSanofi VenturesThe Rise FundTPG Life Sciences InnovationsEnavate SciencesUPMC EnterprisesLeaps By BayerSv Health Investors Fund
Description
Sudo Biosciences announced the second close of its upsized Series B financing, bringing the total raised in the round to $147M. The funding will be used to advance two investigational TYK2 candidates into the clinic this year, including a potential first and best-in-class brain-penetrant TYK2 therapeutic for multiple sclerosis, Alzheimer’s Disease, and ALS, as well as a potential first and best-in-class topical TYK2 inhibitor for psoriasis and other immune-mediated dermatologic diseases.
Who to call at Sudo Biosciences, and when
A new round usually means Sudo Biosciences is about to hire and buy. The teams that reach out first get the meeting.
An alert the day Sudo Biosciences raises, hires an executive or expands, scored against what you sell
The decision-makers there, with verified emails
Who you already know at Sudo Biosciences, from your own LinkedIn network
Trusted byOracleSnowflakeCloudflareLinkedInGoogleSalesforce★★★★★4.8/5 on G2
Company Information
Company
Sudo Biosciences
Location
Carmel, Indiana, United States
About
Sudo Biosciences is a clinical-stage biopharmaceutical company developing next-generation TYK2 inhibitors to transform the treatment of immune-mediated diseases. Its pipeline includes a potential first- and best-in-class, once-daily oral, brain-penetrant candidate for multiple sclerosis and other neuroinflammatory conditions, as well as a topical candidate for dermatologic diseases. Based in Carmel, IN and London, U.K., Sudo is advancing novel medicines designed to improve patient lives.
AI made execution free. Knowing first is the whole game now.
Fundz sees it the moment Sudo Biosciences raises, hires an exec or expands, usually minutes after it happens, and tells you who to reach.
CarmelBiotechnologyHealth CareTherapeuticsBiopharmaBiotechnology Research